Cargando…

Microglial Ion Channels as Potential Targets for Neuroprotection in Parkinson's Disease

Parkinson's disease (PD) is a chronic, degenerative neurological disorder that is estimated to affect at least 1 million individuals in the USA and over 10 million worldwide. It is thought that the loss of neurons and development of inclusion bodies occur gradually over decades until they progr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Richardson, Jason R., Hossain, Muhammad M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2013
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3832972/ https://www.ncbi.nlm.nih.gov/pubmed/24288626 http://dx.doi.org/10.1155/2013/587418

Ejemplares similares

Roles of Microglial Ion Channel in Neurodegenerative Diseases
por: Cojocaru, Alexandru, et al.
Publicado: (2021)

Microglial KCa3.1 Channels as a Potential Therapeutic Target for Alzheimer's Disease
por: Maezawa, Izumi, et al.
Publicado: (2012)

The Neuroprotective Disease-Modifying Potential of Psychotropics in Parkinson's Disease
por: Lauterbach, Edward C., et al.
Publicado: (2012)

Multifunctional Metallothioneins as a Target for Neuroprotection in Parkinson’s Disease
por: Miyazaki, Ikuko, et al.
Publicado: (2023)

Oxidative Stress and Microglial Cells in Parkinson's Disease
por: Peterson, Lynda J., et al.
Publicado: (2012)

SYK coordinates neuroprotective microglial responses in neurodegenerative disease
por: Ennerfelt, Hannah, et al.
Publicado: (2022)

Pathological histone acetylation in Parkinson’s disease: Neuroprotection and inhibition of microglial activation through SIRT 2 inhibition
por: Harrison, Ian F., et al.
Publicado: (2018)

Targeting AMPK Signaling as a Neuroprotective Strategy in Parkinson’s Disease
por: Curry, Daniel W., et al.
Publicado: (2018)

Anti-Neuroinflammatory Effects of the Calcium Channel Blocker Nicardipine on Microglial Cells: Implications for Neuroprotection
por: Huang, Bor-Ren, et al.
Publicado: (2014)

Acid-sensing ion channels: potential therapeutic targets for neurologic diseases
por: Liu, Sha, et al.
Publicado: (2015)

Recent Advances on the Neuroprotective Potential of Antioxidants in Experimental Models of Parkinson’s Disease
por: Koppula, Sushruta, et al.
Publicado: (2012)

Growth differentiation factor 5: a neurotrophic factor with neuroprotective potential in Parkinson’s disease
por: Goulding, Susan R., et al.
Publicado: (2021)

Targeting Microglial K(ATP) Channels to Treat Neurodegenerative Diseases: A Mitochondrial Issue
por: Rodríguez, Manuel J., et al.
Publicado: (2013)

Placental ion channels: potential target of chemical exposure
por: Zhao, Yi, et al.
Publicado: (2022)

Targeting Microglial Activation States as a Therapeutic Avenue in Parkinson’s Disease
por: Subramaniam, Sudhakar R., et al.
Publicado: (2017)

Microglial Phagocytosis and Its Regulation: A Therapeutic Target in Parkinson’s Disease?
por: Janda, Elzbieta, et al.
Publicado: (2018)

Microglial ion channels: Key players in non-cell autonomous neurodegeneration
por: Sarkar, Souvarish
Publicado: (2022)

Targeting the noradrenergic system for anti-inflammatory and neuroprotective effects: implications for Parkinson's disease
por: O’Neill, Eoin, et al.
Publicado: (2018)

Elucidating the Neuroprotective Role of PPARs in Parkinson’s Disease: A Neoteric and Prospective Target
por: Behl, Tapan, et al.
Publicado: (2021)

Neuroprotective Function of DJ-1 in Parkinson's Disease
por: Ariga, Hiroyoshi, et al.
Publicado: (2013)

Neuroprotective potential of Beta vulgaris L. in Parkinson's disease
por: Nade, Vandana S., et al.
Publicado: (2015)

Neuroprotection or Neurotoxicity of Illicit Drugs on Parkinson’s Disease
por: Ferreira, Carla, et al.
Publicado: (2020)

The role of microglial autophagy in Parkinson’s disease
por: Zhu, Rui, et al.
Publicado: (2022)

Voltage-Gated Proton Channel Hv1 Regulates Neuroinflammation and Dopaminergic Neurodegeneration in Parkinson’s Disease Models
por: Neal, Matthew L., et al.
Publicado: (2023)

Neuroprotection and Disease Modification by Astrocytes and Microglia in Parkinson Disease
por: Takahashi, Shinichi, et al.
Publicado: (2022)

Transmembrane Protein 175, a Lysosomal Ion Channel Related to Parkinson’s Disease
por: Tang, Tuoxian, et al.
Publicado: (2023)

Mitochondrial Dysfunction in Parkinson's Disease: Pathogenesis and Neuroprotection
por: Mounsey, Ross B., et al.
Publicado: (2010)

Microglial inflammation and phagocytosis in Alzheimer's disease: Potential therapeutic targets
por: Nizami, Sohaib, et al.
Publicado: (2019)

Microglial autophagy in Alzheimer’s disease and Parkinson’s disease
por: Wang, Zhifu, et al.
Publicado: (2023)

Voltage-Gated Ca(2+) Channels in Dopaminergic Substantia Nigra Neurons: Therapeutic Targets for Neuroprotection in Parkinson's Disease?
por: Ortner, Nadine J.
Publicado: (2021)

Microglial Phenotypes and Their Relationship to the Cannabinoid System: Therapeutic Implications for Parkinson’s Disease
por: Kelly, Rachel, et al.
Publicado: (2020)

Marine Toxins Targeting Ion Channels
por: Arias, Hugo R.
Publicado: (2006)

Neuroprotection in Parkinson’s disease: facts and hopes
por: Salamon, András, et al.
Publicado: (2019)

On the role of endogenous neurotoxins and neuroprotection in Parkinson's disease
por: Segura-Aguilar, Juan
Publicado: (2017)

Microglial Potassium Channels: From Homeostasis to Neurodegeneration
por: Cocozza, Germana, et al.
Publicado: (2021)

Mitochondrial Metabolism as Target of the Neuroprotective Role of Erythropoietin in Parkinson’s Disease
por: Rey, Federica, et al.
Publicado: (2021)

Current Drugs and Potential Future Neuroprotective Compounds for Parkinson’s Disease
por: Carrera, Iván, et al.
Publicado: (2019)

Neuroprotective potential of ferulic acid in the rotenone model of Parkinson’s disease
por: Ojha, Shreesh, et al.
Publicado: (2015)

Blocking microglial activation of reactive astrocytes is neuroprotective in models of Alzheimer’s disease
por: Park, Jong-Sung, et al.
Publicado: (2021)

Neuroprotection by immunomodulatory agents in animal models of Parkinson’s disease
por: Martinez, Bridget, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_gac4c8mc58hh6pn080mgjurnoh